Acerta Pharmaceuticals is being forced to retract claims of a therapeutic benefit of acalabrutinib in a mouse model of pancreatic cancer that was published in three medical journals two years ago due to falsified data.

Verastem, Inc.’s experimental blood cancer drug hit its endpoints in a Phase III trial and the news sent shares of company stock up more than 30 percent.

Celltrion Inc. and Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration accepted for review the Biologics License Application for CT-P10, a proposed Monoclonal Antibody (mAb) biosimilar to Rituxan (rituximab), which is used to treat patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.

The U.S. FDA approved Genentech’s Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with certain blood cancers.